Vetter and Sentry BioPharma Services establish preferred partnership agreement

Supports a streamlined path from filling lab to clinic for early-stage study drugs

06-May-2010 - USA

Vetter and Sentry BioPharma Servicesy announced that they have signed a preferred partnership agreement. Vetter will fill early-stage, high-value biopharmaceuticals at its Chicago facility; Sentry will label, package and ship the clinical supplies from its site in Indianapolis, Indiana. The collaboration will help streamline the path of study drugs from filling lab to clinic while safeguarding product integrity.

Said Peter Soelkner, Vetter managing director, “Our partnership with Sentry affirms our mutual commitment to helping clients get high-quality products to market quickly and efficiently. It also affirms Vetter’s commitment to the North American market.” The Chicago facility, which focuses on preclinical to phase II projects, is Vetter’s first outside of Germany and is an expansion of Vetter Development Service. It will be operational at the beginning of Q4 2010.

“We’re proud to partner with Vetter,” said Jennifer Marcum Sentry’s chief executive officer. “Both of our companies share the same dedication to the quality and safety of our clients’ products.” Sentry was recently awarded a contract by The Centers for Disease Control & Prevention (CDC) to store and distribute influenza vaccine for the U.S. National Strategic Reserve. “In addition, we’re both privately held companies with central U.S. locations allowing rapid response to industry needs and accessibility to clients across North America.”

https://www.bionity.com/en/news/117262/vetter-and-sentry-biopharma-services-establish-preferred-partnership-agreement.html